Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical practice. Objectives: We aimed to provide a comprehe...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
SAGE Publishing,
2024-10-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |